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Abstract
 
Chronic inflammation contributes to carcinogenesis, but the underlying mechanisms are poorly
understood. We report that aged granulocyte-macrophage colony stimulating factor (GM-CSF)-
deficient mice develop a systemic lupus erythematosis (SLE)-like disorder associated with the
impaired phagocytosis of apoptotic cells. Concurrent deficiency of interferon (IFN)-
 
  
 
attenuates
the SLE, but promotes the formation of diverse hematologic and solid neoplasms within a back-
ground of persistent infection and inflammation. Whereas activated B cells show a resistance to
fas-induced apoptosis, antimicrobial therapy prevents lymphomagenesis and solid tumor devel-
opment. These findings demonstrate that the interplay of infectious agents with cytokine-medi-
ated regulation of immune homeostasis is a critical determinant of cancer susceptibility.
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Introduction
 
There is compelling evidence that chronic inflammation
increases the risk of neoplasia (1). Diverse autoimmune dis-
eases predispose to B cell lymphomas and visceral malig-
nancies (2). Persistent infections with 
 
Helicobacter pylori
 
 or
hepatitis B and C virus contribute to cancers of the stom-
ach and liver (3). Inflammatory syndromes of the intestinal
or bronchial epithelia promote carcinomas of the colon and
lung (4). In these pathologies, unresolved inflammation
provokes cell turnover, which together with carcinogen-
or phagocyte-induced DNA damage, eventually culminates
in transformation (5). The genetic factors that control the
progression from chronic inflammation to cancer, how-
ever, are poorly defined.
As vaccination with irradiated tumor cells engineered to
secrete GM-CSF or, to a lesser extent IL-3, stimulates tu-
mor destruction (6), we hypothesized that the endogenous
production of these cytokines function in tumor suppres-
sion. Previous work revealed that GM-CSF– or GM-CSF/
IL-3–deficient mice manifest a lung pathology resembling
pulmonary alveolar proteinosis and specific immune defects
that confer an increased susceptibility to pathogen challenge
(7–9). Here we show that deficiencies of GM-CSF and
IFN-
 
 
 
 modulate the spontaneous development of inflamma-
tion, infection, and cancer.
 
Materials and Methods
 
Mice.
 
GM-CSF– (7), GM-CSF/IL-3– (9), and IFN-
 
 
 
– (10)
deficient mice were backcrossed at least nine generations onto the
C57Bl/6 strain and housed under specific pathogen-free condi-
tions. Homozygous double and triple deficient mice were ob-
tained by intercrossing, and the genotypes were confirmed by
PCR. One cohort of GM-CSF/IL-3/IFN-
 
 
 
–deficient mice was
maintained from birth on enrofloxacin (Baytril
 
®
 
; Bayer) dissolved
in chlorinated drinking water (85 mg/liter corresponding to a
dose of 50 mg/kg). All mouse experiments were approved by the
AAALAC-accredited Dana-Farber Cancer Institute IACUC.
 
Pathology.
 
Tissues were fixed in 10% neutral buffered forma-
lin, processed routinely and embedded in paraffin. Immunohis-
tochemistry was performed using standard techniques with mono-
clonal antibodies to CD4, CD8, B220, and Ig-
 
 
 
 (BD Biosciences).
 
ELISAs.
 
Anti-double stranded DNA antibodies were mea-
sured by adding sera (diluted 1:100 in PBS) to 96 well ELISA
plates (Nunc) coated with S1 nuclease-treated calf thymus DNA
as described (11). After washing, the plates were incubated with
an alkaline phosphatase-conjugated goat anti–mouse IgG (Jack-
son ImmunoResearch Laboratories) and developed with p-nitro-
phenyl phosphate (Boehringer). The absorbances at 405 nm were
determined. Anti-C1q reactivity was measured by adding sera
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(diluted 1:50 in PBS/1M NaCl) to an ELISA plate coated with
human C1q (Quidel Corp.) as described (12). After washing, the
plates were incubated with an alkaline phosphatase–conjugated
goat anti–mouse IgG (Jackson ImmunoResearch Laboratories)
and developed as above. Serum immunoglobulins were quantified
with an ELISA using antibodies from Southern Biotechnology
Associates, Inc. and BD Biosciences according to the manufac-
turer’s recommendations. B cell supernatants were concentrated
with Microcon YM-3 filters (Millipore) and analyzed in a sand-
wich ELISA with anti–TNF-
 
 
 
 or anti–IFN-
 
 
 
 monoclonal anti-
bodies (BD Biosciences). The plates were developed with strepta-
vidin-linked europium (Wallac Oy), and the fluorescence was
measured with a Wallac Victor
 
2
 
 1420 multilabel counter.
 
Phagocytosis of Apoptotic Cell.
 
Thymocytes from 3–5-wk-old
GM-CSF–deficient mice were exposed to 1 
 
 
 
M dexamethasone
in RPMI plus 10% fetal calf serum for 6 h to induce a 60% an-
nexin V positive and 95% propidium iodide negative population.
10
 
7
 
 treated thymocytes were injected into the peritoneal cavities of
3–4-mo-old wild-type, GM-CSF–, or GM-CSF/IL-3–deficient
mice. 30 min later the animals were killed and the peritoneal cavi-
ties lavaged with 3 ml of ice-cold PBS/0.3% BSA/0.03% EDTA/
0.15% NaN
 
3
 
. Cytospins were stained with Diff-Quik (Dade
Behring AG). FACS
 
®
 
 analysis of phagocytosis was performed by
labeling the treated thymocytes before injection with 5- (and 6-)
carboxytetramethylrhodamine, succinimidyl ester (5[6]-TAMRA,
SE; Molecular Probes) as described (13). Macrophages were de-
tected with FITC-conjugated-Mac-1 (BD Biosciences).
 
Lymphomas.
 
Tumors were excised, processed to single cells,
and cryopreserved. Lymphoma-derived DNA was digested with
HindIII or EcoR1 and analyzed by southern using a J
 
 
 
 or J
 
H
 
probe, respectively, as described (14, 15). Single cell lymphoma
suspensions were stimulated with antibodies to CD40 (BD Bio-
sciences), and spectral karyotyping of metaphase spreads was per-
formed as described (15).
 
Apoptosis Assays.
 
Enriched B cells (90% pure) were obtained
from spleens using negative selection with antibodies against
CD4, CD8, and Mac-1 (Cedarlane). 5 
 
 
 
 10
 
6
 
 cells were stimu-
lated for 48 h with 1 
 
 
 
g of anti-CD40 antibody or LPS (50 
 
 
 
g)
in 1 ml of RPMI and 10% fetal calf serum (resulting cultures were
 
 
 
90% B cells). 10
 
6
 
 cell aliquots were then incubated with 1 
 
 
 
g of
anti-fas antibody (Jo2; BD Biosciences), 100 
 
 
 
M etoposide
(Sigma-Aldrich), 1 
 
 
 
M staurosporine (Sigma-Aldrich), or 2 
 
 
 
g/
ml of actinomycin D (Sigma-Aldrich) for 12 h and cell viability
determined by trypan blue exclusion. Anti–mouse TNF-
 
 
 
, iso-
type control antibodies (1 
 
 
 
g), and recombinant cytokines were
from BD Biosciences.
 
Online Supplemental Material.
 
The supplemental figures
show clonal Ig heavy chain gene rearrangements (Fig. S1 A)
and spectral karyotype (Fig. S1 B) of six B cell lymphomas.
The supplemental tables detail tumor types (Table S1) and se-
lected pathologies (Table S2) in GM-CSF/IFN-
 
 
 
– and GM-
CSF/IL-3/IFN-
 
 
 
–deficient mice. Online supplemental mate-
rial is available at http://www.jem.org/cgi/content/full/
jem.20021258/DC1.
Figure 1. Aged GM-CSF– and GM-CSF/
IL-3–deficient mice develop a SLE-like disor-
der. (A) Membrano-proliferative glomerulone-
phritis with Ig deposition in a GM-CSF-defi-
cient mouse, anti-  antibody, original
magnification  400. (B) B220  B cell aggre-
gates in the renal pelvis of a GM-CSF–deficient
mouse, original magnification  400. (C) Anti-
double stranded DNA antibodies. (D) Anti-
C1q reactivity.T
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Results
 
GM-CSF–deficient Mice Develop SLE.
 
While earlier
work delineated a pulmonary alveolar proteinosis-like dis-
ease in GM-CSF– and GM-CSF/IL-3–deficient mice (7,
9), pathologic analysis of aged mutant animals (8
 
 
 
 months)
on the C57Bl/6, but not Balb/c background, unexpectedly
revealed immune-mediated glomerulonephritis with B and
T cell aggregates in the renal pelvis and liver (Fig. 1, A and
B; similar findings in 22/22 GM-CSF– and 17/17 GM-
CSF/IL-3–deficient mice). Consistent with these lesions, a
significant proportion of GM-CSF–and GM-CSF/IL-3–
deficient mice generated anti-double-stranded DNA anti-
bodies and anti-C1q-reactivity (Fig. 1, C and D). To-
gether, these pathologic and serologic features characterize
a SLE-like disorder in older mutant animals.
The mechanisms underlying SLE in several murine mod-
els involve the impaired phagocytosis of apoptotic cells (16).
To test whether GM-CSF/IL-3 deficiency results in a simi-
lar defect, we injected dexamethasone-induced apoptotic
thymocytes into peritoneal cavities and measured their
phagocytosis by resident macrophages (13). Cytospins of
peritoneal washings disclosed a marked reduction in the up-
take of apoptotic bodies by macrophages from mutant mice
compared with wild-type animals (Fig. 2, A and B). Similar
defects were also present in GM-CSF deficient mice (5/5
animals examined, unpublished data). Moreover, fluorescent
labeling of thymocytes with 5- (and 6-) carboxytetramethyl-
rhodamine, succinimidyl ester (5[6]-TAMRA, SE) revealed
that fewer than one-third of the Mac-1–positive cells from
GM-CSF/IL-3–deficient mice were associated with apop-
totic material, in contrast to more than three-quarters of the
 
Mac-1 positive cells from control animals (Fig. 2, C and D).
This compromised phagocytosis of apoptotic cells is consis-
tent with prior work showing the defective uptake of pul-
monary surfactant, bacteria, and latex beads by alveolar mac-
rophages from mutant mice (17). Whereas all mutant mice
analyzed showed the impaired phagocytosis of apoptotic
cells, the variable titers of anti-dsDNA antibodies indicate
that additional factors contribute to disease severity.
 
GM-CSF/IFN-
 
 
 
– and GM-CSF/IL-3/IFN-
 
 
 
–deficient
Mice.
 
Despite the autoimmune disease, GM-CSF– and
GM-CSF/IL-3-deficient mice failed to manifest an increase
in spontaneous tumor formation over 14 mo of observa-
tion. As IFN-
 
 
 
–deficient mice display an enhanced sus-
ceptibility to chemical carcinogenesis (18–20), we tested
whether these cytokines cooperate in tumor suppression by
generating compound knockout animals. Surprisingly,
GM-CSF/IFN-
 
 
 
– and GM-CSF/IL-3/IFN-
 
 
 
–deficient
mice demonstrated reduced survival compared with paren-
tal strains (Fig. 3 A). Whereas the litter sizes were nearly
normal, 
 
 
 
40% of the newborn animals succumbed to over-
whelming pneumonia during the first few weeks of life
(Fig. 3 C). Lung washings consistently grew 
 
Pasteurella pneu-
motropica
 
, a gram-negative coccobacillus that normally colo-
nizes the oropharynx of rodents without causing disease
(21). Lethal infection in the mutant animals likely reflects, at
least in part, diminished bacterial ingestion and killing.
Surviving 2–4-mo-old GM-CSF/IFN-
 
 
 
–deficient mice
manifested no alterations in the numbers of circulating blood
cells, but GM-CSF/IL-3/IFN-
 
 
 
–deficient animals showed a
mild eosinophilia (0.29 
 
 
 
 0.12 
 
 
 
 10
 
3
 
, GM-CSF/IL-3/IFN-
Figure 2. Impaired phagocytosis of apoptotic
cells in GM-CSF– and GM-CSF/IL-3–defi-
cient mice. Dexamethasone-induced apoptotic
thymocytes from GM-CSF–deficient mice
were injected into the peritoneal cavities of
wild-type or GM-CSF/IL-3–deficient mice.
Stained cytospins of harvested cells from: (A)
wild-type mouse, original magnification  400.
(B) GM-CSF/IL-3–deficient mouse, original
magnification   400. Similar results were ob-
tained in five experiments, and GM-CSF-defi-
cient mice manifested comparable defects. (C
and D) Apoptotic thymocytes were labeled
with 5[6]-TAMRA before injection, and
FACS® was used to analyze the harvested peri-
toneal cells. (C) Wild-type mouse. (D) GM-
CSF/IL-3–deficient mouse. Similar results were
found in six experiments.T
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–deficient versus 0.08 
 
 
 
 0.03 
 
 
 
 10
 
3
 
, wild-type; P 
 
 
 
0.0001) that was comparable to GM-CSF/IL-3–deficient
mice (0.32 
 
 
 
 0.10 
 
 
 
 10
 
3
 
; reference 9). The thymi of GM-
CSF/IFN-
 
 
 
– and GM-CSF/IL-3/IFN-
 
 
 
–deficient animals
maintained normal T cell maturation, and the spleens con-
tained normal numbers of B220, CD3, CD4, CD8, NK1.1,
NK1.1-T, and CD11c-positive cells, although Gr-1 and
Mac-1 positive cells were increased twofold.
Over time GM-CSF/IFN-
 
 
 
– and GM-CSF/IL-3/IFN-
 
 
 
–deficient mice gradually became moribund, with most
requiring sacrifice by 14 mo. At autopsy, acute and chronic
inflammatory reactions were present in many organs, par-
ticularly the lungs, soft tissues, lymph nodes, ovaries, adre-
nal glands, and liver (Fig. 3 D). 
 
Pasteurella pneumotropica
 
 and
enterococcal species were frequently cultured from these
lesions. Bone marrow myeloid hyperplasia and splenic ex-
tra-medullary hematopoiesis were associated with the per-
sistent infections. Inflammatory lesions were present in 39/
45 mice examined.
In contrast to the intense inflammatory responses, the
SLE-like disorder was attenuated in GM-CSF/IFN-
 
 
 
– and
GM-CSF/IL-3/IFN-
 
 
 
–deficient mice compared with
GM-CSF– and GM-CSF/IL-3–deficient animals. Lym-
phoid aggregates were absent from the renal pelvis, and
the immune-mediated glomerulonephritis was less severe.
Moreover, anti-double-stranded DNA antibodies and anti-
C1q reactivity were reduced (Fig. 1, C and D). Together,
these results reveal a critical role for IFN-
 
 
 
 in the SLE in-
duced by GM-CSF deficiency and are in accordance with
the requirement for IFN-
 
 
 
 in the SLE caused by defective
fas/fas-ligand function (22).
 
Spontaneous Tumors.
 
Within the background of chronic
infection and inflammation, a high proportion of GM-CSF/
IFN-
 
 
 
– and GM-CSF/IL-3/IFN-
 
 
 
–deficient mice devel-
Figure 3. Infection, inflammation, and
cancer in GM-CSF/IFN- – and GM-CSF/
IL-3/IFN- –deficient mice. (A) Survival
curves for mice singly or multiply deficient
in GM-CSF, IL-3, and IFN- . The num-
bers of animals per cohort were: GM-CSF/
IL-3/IFN- – (n   29), GM-CSF/IFN- –
(n   44), IFN- – (n   14), GM-CSF–
(n    18), GM-CSF/IL-3– (n    18). (B)
Spectrum and incidence of spontaneous
tumors. The number of mice harboring
tumors at autopsy is shown. (C) Lethal bac-
terial pneumonia, H&E stain, original mag-
nification   400. (D) Granulomatous in-
flammation with multinucleated giant cells,
H&E stain, original magnification  400.
(E) Plasmacytoid lymphoma, H&E stain,
original magnification  400. (F) High
grade large cell lymphoma, H&E stain, orig-
inal magnification  400. (G) Choriocarci-
noma, H&E stain, original magnification
 200. (H) Mucin positive biliary tract/liver
carcinoma, mucicarmine stain, original
magnification  400.T
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oped lymphoproliferative diseases (Fig. 3 B, online supple-
mental Table S1). Atypical lymphoid hyperplasias (23) orig-
inating in mesenteric lymph nodes or Peyer’s patches
frequently evolved to mature B cell lymphomas (B220 ,
sIg  by immunohistochemistry) involving the liver, spleen,
and other organs (36/40 lymphomas examined were B cell).
Pathologically, the tumors ranged from low-grade lesions
with plasmacytoid features to high-grade large cell expan-
sions with abundant mitoses (Fig. 3, E and F). Southern
analysis of immunoglobulin light and heavy chain gene re-
arrangements established that the proliferations were clonal
(Fig. 4 A, and online supplemental Fig. S1 A). Spectral
karyotyping further disclosed chromosomal translocations
and aneuploidy in 3 of 6 tumors examined (Fig. 4 B, and
online Supplemental Fig. S1 B). Three of three lymphomas
tested were efficiently transplanted into young GM-CSF/
IL-3/IFN- –deficient recipients (unpublished data).
In addition to the lymphomas, nearly 50% of the GM-
CSF/IFN- – and GM-CSF/IL-3/IFN- –deficient mice
developed solid tumors (Fig. 3 B, online supplemental Ta-
ble S1, online supplemental Table S2). The pathologies ob-
served ranged from lesions that resemble well-described
benign tumors in the human to carcinomas with me-
tastases. Ovarian tumors were the most common, with 6/
13 double deficient and 4/4 triple deficient females mani-
festing choriocarcinomas (Fig. 3 G), luteomas, or terato-
mas. The broad spectrum of tumors also included carcino-
mas of the biliary tract/liver (Fig. 3 H), salivary gland, and
bladder as well as adenomas/hyperplasias of the pancreatic
islets, seminal vesicle, and osteochondral junction. It is
noteworthy that 4/29 double deficient and 4/16 triple de-
ficient mice showed multiple solid lesions.
Tumor development required the combined deficiency
of GM-CSF and IFN- . Histopathologic analysis of aged
animals (12–17 mo) revealed no tumors in 7 wild-type
mice, 2 cases of atypical hyperplasia and 1 luteoma in 15
GM-CSF-deficient mice, 2 cases of atypical hyperplasia in
17 GM-CSF/IL-3–deficient mice, and 1 luteoma and 1 is-
let cell hyperplasia in 13 IFN- –deficient mice. Moreover,
gross autopsy of 28 additional IFN- –deficient animals up
to 27 mo of age disclosed only a single case of lymphoma
(B220 ). Most GM-CSF- and GM-CSF/IL-3–deficient
mice succumbed to pulmonary alveolar proteinosis by 18
mo, precluding a longer-term study of spontaneous tumor
development in these strains.
Lymphomagenesis. To explore the mechanisms underly-
ing spontaneous tumor formation in the compound cyto-
kine deficient mice, we characterized potential precursor
lesions in B cell lymphomagenesis. Although secondary
lymphoid tissues of 2–3 mo old mice did not show evi-
dence of atypical hyperplasia or clonal proliferation, germi-
nal centers were enlarged. Consistent with these findings,
serum IgG1 levels were higher in mutant mice than con-
trols (1,811   329, GM-CSF/IFN- –deficient versus
921    172, wild-type; P    0.0003); serum IgG2b
(4,431   2,150 versus 2,240   730) and IgE levels (845  
709 versus 330   427) were also increased, but these did
not reach statistical significance.
Unresolved infection and inflammation likely contribute
to the persistent B cell activation in GM-CSF/IFN- –
Figure 4. B cell  lymphomas. (A)
Tumor-derived DNA from six differ-
ent lymphomas was analyzed by
southern using a J  probe. The germ-
line band is 2.7 kb. (B) Single cell
lymphoma suspensions were stimu-
lated with anti-CD40 antibodies, and
spectral karyotyping of metaphase
spreads was performed. Shown are
clonal 12:1, 4:13, 13:4, and 1:6 chro-
mosomal translocations in one case.
Chromosomal abnormalities were
found in 3 of 6 tumors. (C) Impaired
fas-mediated apoptosis. Enriched
splenic B cells (90% pure) were stimu-
lated for 48 h with anti-CD40 anti-
body (after activation,  90% B cells),
and then 106 cell aliquots were incu-
bated with 1  g of anti-fas antibody,
100  M etoposide, 1  M staurospo-
rine, or 2  g/ml of actinomycin D
for 12 h and cell viability determined.
Data are pooled from six experiments;
fas-treated wild-type versus fas-treated
GM-CSF/IL-3/IFN-  deficient, P  
0.0001. Similar results were obtained
with LPS (50  g) stimulated B cells.
A comparable fas-resistance was also
found with GM-CSF/IFN- –defi-
cient B cells. (D) TNF-  and IFN- 
are required for fas-mediated B cell
apoptosis. The data are pooled from
four experiments.T
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and GM-CSF/IL-3/IFN- –deficient mice. To determine
whether intrinsic B cell defects were also involved, we
evaluated the responses of purified B cells to anti-CD40
antibodies or lipopolysaccharide. No significant differences
in the cell cycle profiles or up-regulation of surface MHC
II, B7–1, and fas expression were detected between the
mutant and wild type cells after 48 h of stimulation (un-
published data). Nonetheless, activated B cells from GM-
CSF/IL-3/IFN- –deficient mice manifested a resistance to
fas-mediated apoptosis (P    0.0001, versus wild-type),
whereas activated B cells from IFN- –, GM-CSF–, or
GM-CSF/IL-3–deficient animals displayed fas sensitivities
equivalent to controls (Fig. 4 C). The killing induced with
etoposide, staurosporine, and actinomycin, in contrast, was
comparable among all the strains.
As soluble factors modulate target cell fas sensitivity (24),
we tested whether conditioned media from activated wild-
type B cells could reverse the defective response of GM-
CSF/IL-3/IFN- –deficient B cells. As illustrated in Fig. 4
D, the addition of wild-type supernatants to mutant cul-
tures restored the fas sensitivity, suggesting that the im-
paired function of one or more cytokines might be re-
sponsible for the defect. Indeed, anti–TNF-  antibodies
significantly inhibited fas killing in wild-type B cells, and
supernatants from wild-type cultures contained fivefold
more immunoreactive TNF-  (6.7   0.44 pg/5   106
cells) than GM-CSF/IL-3/IFN- –deficient cultures (1.3  
0.21 pg/5   106 cells), as measured by ELISA. The restora-
tion of normal TNF-  levels in the mutant cultures with
recombinant cytokine partially corrected the fas resistance
(Fig. 4 D). However, the restoration of both wild-type
TNF-  and IFN-  levels (2.5   0.06 pg/5   106 cells)
completely restored the fas sensitivity of mutant cells.
These results establish a dual requirement for TNF-  and
IFN-  in fas-mediated B cell apoptosis. As aged fas-defi-
cient mice harbor B cell lymphomas (25), the apoptotic
defect delineated here may contribute to tumor develop-
ment. However, further studies are required to determine
whether a similar TNF-  deficiency is present in vivo.
Antibiotics Suppress Tumor Formation. As microbial
agents contribute to lymphomagenesis and solid tumor de-
velopment in humans, we maintained a cohort of 24 GM-
CSF/IL-3/IFN- -deficient mice from birth on enrofloxa-
cin. Consistent with the ability of this antibiotic to suppress
Pasteurella pneumotropica and enterococcal species (21), early
infectious deaths were eliminated from the cohort. More-
over, antimicrobial therapy prevented tumor formation in
aged animals. No lymphomas or solid tumors were detected
in 19 mice autopsied at 14 mo (P   0.001 for lymphomas,
P   0.001 for all solid tumors, and P   0.03 for carcinomas,
by the Fisher exact test, compared with the untreated co-
hort). One animal showed atypical thymic hyperplasia; 3
mice died of fighting-related injuries and 2 of unknown
causes between 8 and 12 mo. The suppression of tumor for-
mation was associated with a marked reduction in chronic
inflammatory lesions; of 9 animals studied by histopathol-
ogy, only 1 showed mild cholangitis and pancreatitis. In
contrast, CD40-activated B cells from enrofloxacin-treated
mice displayed a comparable fas-resistance to lymphocytes
from untreated GM-CSF/IL-3/IFN- –deficient animals (2
mice analyzed, unpublished data). Additional experiments
are required to determine whether anti-microbial therapy
will suppress tumor formation over a longer time period.
Discussion
Our studies establish that the interplay of GM-CSF and
IFN-  deficiencies modulates susceptibility to inflammation,
infection, and cancer. In this context, recent experiments in
C. elegans demonstrate that a partial impairment of caspase
activity cooperates with an engulfment defect to allow the
recovery of some cells otherwise committed to apoptosis
(26, 27). We propose that in the germinal center reactions of
GM-CSF/IFN- –deficient mice, B cell survival is similarly
enhanced by a combination of the fas resistance and the im-
paired phagocytosis of early apoptotic cells (28). In the set-
ting of chronic antigenic stimulation, this expanded pool of
B cells acquires an increased risk for transforming mutations
due to rare errors in somatic hypermutation (29).
Our finding that antimicrobial therapy inhibits both
lymphomagenesis and solid tumor formation is consistent
with clinical observations that a variety of infectious agents
are linked with some human B cell lymphomas and solid
neoplasms, including carcinomas of the stomach, liver, bil-
iary tract, and bladder (3). The model reported here should
prove useful for clarifying whether microbes function as
cofactors that drive target cell proliferation and/or directly
mediate target cell transformation. The antibiotic-mediated
suppression of inflammatory pathology also supports the
idea that tissue damage secondary to unresolved inflamma-
tion is an important contributor to carcinogenesis (5). To-
gether, these results indicate that the complex interaction
of infectious agents and defective immune homeostasis is a
critical determinant of cancer susceptibility.
Our studies further suggest that the high incidence of T
cell lymphomas recently reported in IFN-  single deficient
mice on the C57Bl/6 background (30) reflects, at least in
part, the involvement of an infectious agent not present in
our colony. Interestingly, spontaneous lymphomas were
not increased in IFN-  single deficient mice on the Balb/c
background, although IFN-  ablation in this strain en-
hanced the B cell lymphomagenesis consequent to perforin
deficiency (30); these latter results are consistent with the
findings presented here.
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